Abstract:ObjectiveTo study the expression of amplified in breast cancer 1 (AIB1) protein in the tissues of ovarian carcinoma and its relationship with clinicopathological factors, and to analyze the predictive value of AIB1 in clinical prognosis of patients with ovarian carcinoma. MethodsImmunohistochemistry was used to detect the expression of AIB1 protein in the tissues of 112 patients with ovarian carcinoma, and compare the AIB1 protein expression levels of patients with various clinicopathological features. The survival analysis was conducted by Kaplan-Meier method. The multivariate analysis was performed to explore the relationship between the expression of AIB1 protein and clinical prognosis of the patients with ovarian carcinoma. ResultsThe positive expression rate of AIB1 protein in the tissues of ovarian carcinoma was 67.9% (76/112). The positive expression rate of AIB1 protein was associated with the degree of the tumor differentiation (χ2=32.483, P＜0.001) and the International Federation of Gynecology and Obstetrics (FIGO) staging (χ2=14.324, P＜0.001), but not with the age (χ2=0.001, P=0.989) or pathological type (χ2=0.106, P=0.745). Compared with the patients with the higher expression of AIB1, the median disease-free survival of patients with the lower expression of AIB1 was longer (48.7 months vs. 36.7 months, χ2=3.026, P=0.022), and there was also extended trend in the median overall survival (60.2 months vs. 43.6 months, χ2=0.916, P=0.055). The multivariate survival analysis showed that FIGO staging (RR=3.396, P=0.021) and AIB1 expression status (RR=1.407, P=0.049) were independent prognostic factors affecting the survival of patients. ConclusionThe overexpression of AIB1 protein is correlated with the degree of differentiation and FIGO staging. Patients with a high expression of AIB1 have poor predicted prognosis. The expression of AIB1 protein can be considered as one of the prognostic indicators in the patients with ovarian carcinoma.

Key words:Ovarian neoplasms,Gene expression,Prognosis,Amplified in breast cancer 1